On this page
Practo appoints Jagnoor Singh CEO; founder Shashank ND Singh becomes executive chairman
Our read
Practo’s CEO transition is likely to convert a profitable Indian health-tech marketplace into a more enterprise- and AI-led healthcare platform, with execution in regulated international markets as the main constraint.
For operators
Practo’s CEO transition gives the company a clearer operating mandate to scale consumer, enterprise and AI healthcare offerings while preserving founder-led strategic oversight.
Watch
Specific launch dates, pricing and adoption metrics for AI-powered products.
Ask next
The report,
Practo appointed COO Jagnoor Singh as CEO and elevated founder Shashank ND Singh to managing director and executive chairman. The profitable digital healthcare platform, growing 40% year-on-year, also expanded B2C, B2B and AI leadership roles as it scales globally.
- Year-on-year growth
- 40%
- Profitable for
- 2.5 years
- Network of doctors and healthcare providers
- 700,000
Who and when
From the report. Source details below
| Jagnoor Singh appointed CEO effective September 1, | 2026 |
|---|---|
| Jagnoor Singh joined as COO in January | 2025 |
| Practo has operated for | 18 years |
Also in the report
- network of 700,000 doctors and healthcare providers
Other figures
- profitable for 2.5 years
Why the change matters
With its founder shifting to executive chairman and a new CEO taking operational control, Practo may become a more structured partner for enterprise healthcare alliances and expansion-led transactions.
What to watch next
- Growth split between consumer consultations, provider SaaS and enterprise healthcare revenue.
- New insurer, employer, hospital-chain or cross-border partnerships.
- International market entry announcements and local regulatory/data-compliance investments.
- Changes in EBITDA margin, customer-acquisition cost, repeat-booking rates and provider retention.
- Whether the founder retains operational influence beyond board and strategic responsibilities.
Likely next moves
Our read of what comes next — analysis, not reported by the source.
- Announce an AI product roadmap covering patient discovery, clinical workflow, care navigation and contact-center automation.
- Elevate or hire leaders for international markets, enterprise sales, data governance and AI safety.
- Pursue partnerships with insurers, employers, hospital chains, diagnostics networks and pharmacy platforms.
- Use profitability to fund selective acquisitions or provider-network partnerships in priority markets.
- Shift investor and partner messaging toward recurring enterprise revenue, AI-enabled unit economics and global addressable market.
The counter-case
The case against this reading — not reported by the source.
The CEO change may be more about formalizing founder control than demonstrating a clean succession: Shashank ND Singh remains managing director and executive chairman, which could blur decision rights and limit Jagnoor Singh's autonomy. Reported profitability and 40% growth need scrutiny on scale, durability, cash generation, customer-acquisition costs, and whether growth is concentrated in lower-margin segments. Global expansion and AI healthcare initiatives are capital-intensive, highly regulated, and vulnerable to stronger incumbents, data-privacy constraints, and uncertain monetization.